UK markets closed

Renalytix Plc (RNLX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.6170-0.0163 (-2.57%)
At close: 04:00PM EDT
0.6229 +0.01 (+0.96%)
After hours: 07:33PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.6333
Open0.6343
Bid0.6130 x 100
Ask0.6208 x 100
Day's range0.6100 - 0.6343
52-week range0.2450 - 4.0380
Volume235,695
Avg. volume1,827,406
Market cap48.874M
Beta (5Y monthly)1.98
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Globe Newswire

    Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15

    LONDON and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its third quarter fiscal year 2024 financial results on Wednesday, May 15, 2024 before U.S. market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST) on the day. Conference

  • PR Newswire

    Pentwater Capital Management LP - Form 8.3 - Renalytix PLC

    Pentwater Capital Management LP - Form 8.3 - Renalytix PLC

  • Globe Newswire

    Renalytix Announces Financing with Expected Size of up to $4 Million

    LONDON and SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75 per NASDAQ ADS ($0.375 per common stock share) (£0.0025 each) (the “Ordinary Shares”) (the “Fundraise”) to DB Capital Partners Healthcare, L.P. (the “Purchaser”), a specialty healthcare institutional investor focused on innovative medical technology that fundamentally changes critical global diseas